Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLR013
MIFTS: 48

Biliary Tract Cancer

Categories: Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Biliary Tract Cancer

About this section

MalaCards integrated aliases for Biliary Tract Cancer:

Name: Biliary Tract Cancer 54 56

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Biliary Tract Cancer

About this section
MalaCards based summary : Biliary Tract Cancer is related to gallbladder cancer and cholangiocarcinoma. An important gene associated with Biliary Tract Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are HIV Life Cycle and PAK Pathway. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 77 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Sources

Related Diseases for Biliary Tract Cancer

About this section

Diseases related to Biliary Tract Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 gallbladder cancer 32.0 EGFR ERBB2 MLH1
2 cholangiocarcinoma 31.5 EGFR ERBB2 MET MUC4 SMAD4
3 lynch syndrome 29.2 EGFR MLH1 TGFBR2
4 pancreatic cancer 28.1 DPYD EGFR ERBB2 MET MUC4 SMAD4
5 gastric cancer 27.7 DPYD EGFR ERBB2 MET MLH1 SMAD4
6 bile duct cancer 11.8
7 breast intraductal proliferative lesion 10.3 EGFR ERBB2
8 progesterone-receptor negative breast cancer 10.3 EGFR ERBB2
9 breast scirrhous carcinoma 10.2 EGFR ERBB2
10 breast squamous cell carcinoma 10.2 EGFR ERBB2
11 microglandular adenosis 10.2 EGFR ERBB2
12 inflammatory breast carcinoma 10.2 EGFR ERBB2
13 luminal breast carcinoma 10.2 EGFR ERBB2
14 acneiform dermatitis 10.2 EGFR ERBB2
15 doxorubicin induced cardiomyopathy 10.2 EGFR MET
16 esophagus adenocarcinoma 10.2 ERBB2 SMAD4
17 lipid-rich carcinoma 10.2 EGFR ERBB2
18 mucinous lung adenocarcinoma 10.2 EGFR ERBB2
19 hidradenocarcinoma 10.2 EGFR ERBB2
20 mammary paget's disease 10.2 EGFR ERBB2
21 familial renal papillary carcinoma 10.2 EGFR MET
22 gallbladder adenocarcinoma 10.2 EGFR ERBB2
23 primary peritoneal carcinoma 10.2 EGFR ERBB2
24 adenosquamous lung carcinoma 10.1 EGFR ERBB2
25 pre-malignant neoplasm 10.1 EGFR ERBB2
26 breast secretory carcinoma 10.1 ERBB2 MUC4
27 spinal chordoma 10.1 EGFR MET
28 hepatocellular carcinoma 10.1
29 wilms tumor 1 10.1
30 wilms tumor 5 10.1
31 wilms tumor 6 10.1
32 intrahepatic cholangiocarcinoma 10.1
33 exanthem 10.0 EGFR ERBB2
34 breast adenocarcinoma 10.0 EGFR ERBB2 SMAD4
35 colorectal cancer 5 10.0 DPYD MLH1
36 in situ carcinoma 10.0 EGFR ERBB2
37 bronchiolo-alveolar adenocarcinoma 10.0 EGFR MUC4
38 adenomyoma 10.0 MLH1 MUC4
39 breast carcinoma in situ 10.0 EGFR ERBB2 MET
40 respiratory system cancer 10.0 EGFR ERBB2 MET
41 breast ductal carcinoma 10.0 EGFR ERBB2 MET
42 insulin-like growth factor i 10.0
43 body mass index quantitative trait locus 1 10.0
44 cholangitis, primary sclerosing 10.0
45 diabetes mellitus 10.0
46 sclerosing cholangitis 10.0
47 cholangitis 10.0
48 hypoxia 10.0
49 mucinous adenocarcinoma 10.0 EGFR MLH1
50 mucoepidermoid carcinoma 10.0 EGFR ERBB2 MUC4

Graphical network of the top 20 diseases related to Biliary Tract Cancer:



Diseases related to Biliary Tract Cancer
Sources

Symptoms & Phenotypes for Biliary Tract Cancer

About this section

GenomeRNAi Phenotypes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.33 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 9.33 EGFR
3 Increased cell viability after pRB stimulation GR00230-A-1 9.26 EGFR ERBB2 MET TGFBR2
4 Increased mitotic index GR00110-A-0 8.8 MET SMAD4 TGFBR2

MGI Mouse Phenotypes related to Biliary Tract Cancer:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.04 EGFR ERBB2 LGR4 MET MLH1 SMAD4
2 digestive/alimentary MP:0005381 10 EGFR ERBB2 LGR4 MET MLH1 SMAD4
3 cardiovascular system MP:0005385 9.99 EGFR ERBB2 LGR4 MET SMAD4 TGFBR2
4 endocrine/exocrine gland MP:0005379 9.95 EGFR ERBB2 LGR4 MET MLH1 SMAD4
5 embryo MP:0005380 9.91 EGFR ERBB2 LGR4 MET SMAD4 TGFBR2
6 craniofacial MP:0005382 9.88 EGFR ERBB2 MET SMAD4 TGFBR2
7 liver/biliary system MP:0005370 9.77 EGFR LGR4 MET SMAD4 TGFBR2
8 neoplasm MP:0002006 9.73 EGFR ERBB2 MET MLH1 SMAD4 TGFBR2
9 muscle MP:0005369 9.72 EGFR ERBB2 MET SMAD4 TGFBR2
10 reproductive system MP:0005389 9.63 DPYD EGFR ERBB2 LGR4 MLH1 SMAD4
11 respiratory system MP:0005388 9.35 EGFR ERBB2 MET MLH1 TGFBR2
12 vision/eye MP:0005391 9.02 EGFR LGR4 MET MLH1 TGFBR2
Sources

Drugs & Therapeutics for Biliary Tract Cancer

About this section

Drugs for Biliary Tract Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
3
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
4
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 61825-94-3 6857599 5310940 9887054 43805
5
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
8
Tegafur Approved, Investigational Phase 3,Phase 2,Phase 1 17902-23-7 5386
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Durvalumab Approved, Investigational Phase 3,Phase 2,Phase 1 1428935-60-7
11
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 7487-88-9 24083
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
13
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
14 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
20
s 1 (combination) Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antidotes Phase 3,Phase 2,Phase 1
23 Emetics Phase 3,Phase 2
24 Protective Agents Phase 3,Phase 2,Phase 1
25 Antiemetics Phase 3,Phase 2
26 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
27 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
28 Nutrients Phase 3,Phase 2,Phase 1,Not Applicable
29 Vitamin B Complex Phase 3,Phase 2,Phase 1
30 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
31 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Hematinics Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
35 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
36 Folate Phase 3,Phase 2,Phase 1
37 Vitamin B9 Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
40 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
41 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
42 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
43 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Not Applicable
44
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
45
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
46
Racepinephrine Approved Phase 2 329-65-7 838
47
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
50
Lenvatinib Approved, Investigational Phase 2 417716-92-8

Interventional clinical trials:

(show top 50) (show all 227)
# Name Status NCT ID Phase Drugs
1 The Effect of Individualized Precision Therapy Programs in Patients With BTC Not yet recruiting NCT02943031 Phase 4
2 X-MAS Biliary Study With Covered Biliary Stent Unknown status NCT01899976 Phase 3
3 GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Completed NCT02182778 Phase 3 Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
4 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
5 Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Completed NCT00939848 Phase 2, Phase 3 gemcitabine;cisplatin;Placebo;cisplatin;cediranib;gemcitabine
6 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
7 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
8 Early Palliative Care on Quality of Life of Advanced Cancer Patients Completed NCT02988635 Phase 3
9 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
10 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
11 A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
12 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
13 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
14 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
15 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
16 A Global Phase III Study of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer Not yet recruiting NCT03875235 Phase 3 Durvalumab;Placebo
17 Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC Not yet recruiting NCT03478488 Phase 3 KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin
18 A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Not yet recruiting NCT02597465 Phase 3 SPARC1507;Reference1507
19 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
20 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
21 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
22 GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Unknown status NCT01859728 Phase 2 Irinotecan;Cisplatin;Cisplatin;Gemcitabine
23 Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01494363 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
24 Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01234051 Phase 2 Docetaxel, Oxaliplatin
25 Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
26 FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Unknown status NCT03110510 Phase 2 Fluorouracil;Irinotecan Hydrochloride;leucovorin calcium
27 Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract Unknown status NCT02632019 Phase 1, Phase 2 Gemcitabine
28 XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy Unknown status NCT02350686 Phase 2 capecitabine;oxaliplatin
29 SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
30 Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer Completed NCT01917617 Phase 2 Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS);Gemcitabine , Cisplatin
31 Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Completed NCT02433639 Phase 2 TH-302 monotherapy
32 Second Line Therapy in Advanced Biliary Tract Cancer Completed NCT01530503 Phase 2 capecitabine and mitomycin;Capecitabine
33 Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer Completed NCT00380588 Phase 2 gemcitabine;cisplatin
34 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Completed NCT02579616 Phase 2 Lenvatinib
35 Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Completed NCT01815307 Phase 2 Gemcitabine;S-1
36 Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer Completed NCT01284413 Phase 1, Phase 2 S-1, Gemcitabine, Cisplatin
37 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Completed NCT01661114 Phase 2 Gemcitabine;5-FU;Cisplatin
38 Salvage mFOLFOX in BTC After Failure of Gemcitabine Completed NCT01127555 Phase 2 5-fluorouracil, leucovorin, oxaliplatin
39 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
40 Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer Completed NCT00832689 Phase 2 Irinotecan and Gemcitabine
41 Gemcitabine and S-1 for Advanced Biliary Tract Cancer Completed NCT02146703 Phase 2 Gemcitabine, and S-1
42 A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers Completed NCT01943864 Phase 2 Trametinib (single tablet);Trametinib (Multiple tablet)
43 Cetuximab + Gemox in Biliary Tract Cancer Completed NCT01216345 Phase 2 Cetuximab + Gemcitabine + Oxaliplatin
44 Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer Completed NCT02558959 Phase 2 Irinotecan;Capecitabine
45 Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin Completed NCT00552149 Phase 2 Gemox, Cetuximab
46 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
47 EXIBIT: Oxaliplatin in Biliary Tract Cancer Completed NCT00174564 Phase 2 oxaliplatin
48 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
49 Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery Completed NCT00553332 Phase 2 selumetinib
50 Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study Completed NCT00747097 Phase 2 gemcitabine + cetuximab

Search NIH Clinical Center for Biliary Tract Cancer

Sources

Genetic Tests for Biliary Tract Cancer

About this section
Sources

Anatomical Context for Biliary Tract Cancer

About this section

MalaCards organs/tissues related to Biliary Tract Cancer:

42
Liver, Skin, Testes, Lung, Nk Cells, Pancreas, Lymph Node
Sources

Publications for Biliary Tract Cancer

About this section

Articles related to Biliary Tract Cancer:

(show top 50) (show all 591)
# Title Authors Year
1
Albumin-Indocyanine Green Evaluation Grading System Predicts Post-Hepatectomy Liver Failure for Biliary Tract Cancer. ( 29339651 )
2019
2
Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. ( 30374530 )
2019
3
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. ( 30581069 )
2019
4
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. ( 30634942 )
2019
5
Biliary tract cancer: current challenges and future prospects. ( 30643463 )
2019
6
Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. ( 30645774 )
2019
7
Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells. ( 30650425 )
2019
8
Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden. ( 30656997 )
2019
9
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. ( 30659304 )
2019
10
The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis. ( 30662546 )
2019
11
Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. ( 30687954 )
2019
12
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. ( 30707660 )
2019
13
Second Line Chemotherapy in Biliary Tract Cancer: Outcome and Prognostic Factors. ( 30716200 )
2019
14
Efficacy and safety of nivolumab for metastatic biliary tract cancer. ( 30774373 )
2019
15
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. ( 30797051 )
2019
16
The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics. ( 30813586 )
2019
17
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. ( 30826661 )
2019
18
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. ( 30856044 )
2019
19
A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing. ( 30908307 )
2019
20
Smoking, alcohol consumption, and risks for biliary tract cancer and intrahepatic bile duct cancer. ( 29760302 )
2018
21
Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer. ( 28905105 )
2018
22
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. ( 28930749 )
2018
23
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. ( 29024931 )
2018
24
Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. ( 29114851 )
2018
25
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. ( 29133140 )
2018
26
Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer. ( 29148857 )
2018
27
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. ( 29224898 )
2018
28
Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. ( 29265948 )
2018
29
First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer. ( 29277797 )
2018
30
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202). ( 29305639 )
2018
31
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. ( 29325521 )
2018
32
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. ( 29334603 )
2018
33
Effect of midkine on gemcitabine resistance in biliary tract cancer. ( 29344648 )
2018
34
Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer. ( 29381586 )
2018
35
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. ( 29448202 )
2018
36
A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). ( 29462482 )
2018
37
Emerging molecular target antagonists for the treatment of biliary tract cancer. ( 29468924 )
2018
38
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. ( 29474549 )
2018
39
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. ( 29491113 )
2018
40
Survival rates are higher in married patients with biliary tract cancer: a population-based study. ( 29507708 )
2018
41
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. ( 29527009 )
2018
42
Diagnostic usefulness of KL-6 concentration of bile in biliary tract cancer. ( 29541466 )
2018
43
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. ( 29562907 )
2018
44
The prognostic impact of differentiation at the invasive front of biliary tract cancer. ( 29572828 )
2018
45
Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis. ( 29578146 )
2018
46
Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study. ( 29594362 )
2018
47
Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients. ( 29608578 )
2018
48
Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. ( 29705791 )
2018
49
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. ( 29705976 )
2018
50
Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. ( 29765232 )
2018
Sources

Variations for Biliary Tract Cancer

About this section
Sources

Expression for Biliary Tract Cancer

About this section
Search GEO for disease gene expression data for Biliary Tract Cancer.
Sources

Pathways for Biliary Tract Cancer

About this section

Pathways related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
HIV Life Cycle 67
Show member pathways
 13.47 EGFR ERBB2 MET MUC4 SMAD4 TGFBR2
2
PAK Pathway 65
Show member pathways
 13.06 EGFR ERBB2 MET SMAD4 TGFBR2
3
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.69 EGFR ERBB2 MET TGFBR2
4
Endometrial cancer 38
Show member pathways
 12.58 EGFR ERBB2 MLH1 SMAD4 TGFBR2
5
MAPK signaling pathway 1 38
12.53 EGFR ERBB2 MET TGFBR2
6
Pathways in cancer 38
12.46 EGFR ERBB2 MET MLH1 SMAD4 TGFBR2
7
ErbB signaling pathway 1 38
Show member pathways
 12.39 EGFR ERBB2 MET
8
MicroRNAs in cancer 38
12.32 EGFR ERBB2 MET
9
Gastric cancer 38
Show member pathways
 12.3 EGFR ERBB2 MET MLH1 SMAD4 TGFBR2
10
mTOR signaling pathway (KEGG) 66
Show member pathways
 12.28 EGFR ERBB2 LGR4 MET
11
Apoptosis Pathway 73
Show member pathways
 12.18 EGFR ERBB2 MET TGFBR2
12
Proteoglycans in cancer 38
12.11 EGFR ERBB2 MET
13
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.01 EGFR ERBB2 MET
14
Integrated Breast Cancer Pathway 1
11.96 EGFR SMAD4 TGFBR2
15
AKT Signaling Pathway 68
11.94 EGFR ERBB2 MET
16
Tyrosine Kinases / Adaptors 4
11.93 EGFR ERBB2 MET
17
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 11.92 EGFR ERBB2 TGFBR2
18
Colorectal Cancer Metastasis 65
11.92 EGFR MLH1 SMAD4 TGFBR2
19
FoxO signaling pathway 38
Show member pathways
 11.88 EGFR SMAD4 TGFBR2
20
TGF-beta Signaling Pathway (WikiPathways) 1
11.85 MET SMAD4 TGFBR2
21
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.84 EGFR MET SMAD4 TGFBR2
22
Direct p53 effectors 1
11.83 EGFR MET MLH1
23
Development_TGF-beta receptor signaling 23
11.53 ERBB2 SMAD4 TGFBR2
24
Central carbon metabolism in cancer 38
11.47 EGFR ERBB2 MET
25
Alzheimers Disease Pathway 65
11.32 EGFR ERBB2
26
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.31 EGFR ERBB2 SMAD4 TGFBR2
27
Signaling events mediated by TCPTP 1
Show member pathways
 11.28 EGFR MET
28
Stabilization and expansion of the E-cadherin adherens junction 1
11.26 EGFR MET
29
G-protein signaling_Cross-talk between Ras-family GTPases 23
11.21 EGFR ERBB2 TGFBR2
30
Adherens junction 38
11.21 EGFR ERBB2 MET SMAD4 TGFBR2
31
Arf6 signaling events 1
11.17 EGFR MET
32
ALK1 signaling events 1
Show member pathways
 11.07 SMAD4 TGFBR2
33
a6b1 and a6b4 Integrin signaling 1
11.04 EGFR ERBB2 MET
34
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.02 SMAD4 TGFBR2
35
NTHi-Induced Signaling 65
10.93 SMAD4 TGFBR2
36
Extracellular vesicle-mediated signaling in recipient cells 1
10.5 EGFR ERBB2 MET SMAD4 TGFBR2
Sources

GO Terms for Biliary Tract Cancer

About this section

Cellular components related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 EGFR ERBB2 LGR4 MET MUC4 TGFBR2
2 receptor complex GO:0043235 9.26 EGFR ERBB2 MET TGFBR2
3 basal plasma membrane GO:0009925 8.8 EGFR ERBB2 MET

Biological processes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.88 EGFR ERBB2 MET TGFBR2
2 protein phosphorylation GO:0006468 9.84 EGFR ERBB2 MET TGFBR2
3 cell surface receptor signaling pathway GO:0007166 9.79 EGFR ERBB2 MET
4 MAPK cascade GO:0000165 9.74 EGFR ERBB2 MET
5 peptidyl-tyrosine phosphorylation GO:0018108 9.67 EGFR ERBB2 MET
6 regulation of cell proliferation GO:0042127 9.65 EGFR SMAD4 TGFBR2
7 cellular response to epidermal growth factor stimulus GO:0071364 9.63 EGFR ERBB2
8 positive regulation of protein kinase B signaling GO:0051897 9.63 EGFR ERBB2 MET
9 positive regulation of epithelial to mesenchymal transition GO:0010718 9.62 SMAD4 TGFBR2
10 hair follicle development GO:0001942 9.61 EGFR LGR4
11 ventricular septum morphogenesis GO:0060412 9.61 SMAD4 TGFBR2
12 gastrulation GO:0007369 9.59 SMAD4 TGFBR2
13 digestive tract development GO:0048565 9.58 LGR4 TGFBR2
14 ERBB2 signaling pathway GO:0038128 9.56 EGFR ERBB2
15 cell proliferation GO:0008283 9.56 EGFR ERBB2 MET SMAD4
16 regulation of cell motility GO:2000145 9.55 EGFR ERBB2
17 cell differentiation GO:0030154 9.54 EGFR LGR4 TGFBR2
18 outflow tract septum morphogenesis GO:0003148 9.52 SMAD4 TGFBR2
19 regulation of ERK1 and ERK2 cascade GO:0070372 9.51 EGFR ERBB2
20 phosphatidylinositol phosphorylation GO:0046854 9.5 EGFR ERBB2 MET
21 secondary palate development GO:0062009 9.4 SMAD4 TGFBR2
22 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.33 EGFR ERBB2 MET
23 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.3 EGFR
24 positive regulation of MAPK cascade GO:0043410 9.13 ERBB2
25 wound healing GO:0042060 9.13 EGFR ERBB2 TGFBR2
26 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.85 EGFR ERBB2 MET MLH1 TGFBR2
2 kinase activity GO:0016301 9.73 EGFR ERBB2 MET TGFBR2
3 protein kinase activity GO:0004672 9.71 EGFR ERBB2 MET TGFBR2
4 protein tyrosine kinase activity GO:0004713 9.54 EGFR ERBB2 MET
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 EGFR ERBB2 MET
6 growth factor binding GO:0019838 9.48 ERBB2 TGFBR2
7 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 MET
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR ERBB2 MET
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR ERBB2 MET
10 transmembrane signaling receptor activity GO:0004888 8.8 EGFR ERBB2 LGR4
Sources

Sources for Biliary Tract Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....